#cbdproducts – “Two Republican members of Congress want answers from the feds about regulations for CBD and other hemp-derived products.
U.S. Reps. Morgan Griffith of Virginia and Brett Guthrie of Kentucky co-signed two letters to U.S. Food and Drug Administration Commissioner Robert Califf in which they question several FDA regulatory practices and also demand action.
“In areas from baby formula to CBD products to tobacco, the FDA has been sluggish in solving problems, it has been unresponsive to Congress, and it has been deficient in the execution of responsibilities given to it by law,” Griffith said in a statement.
“We ultimately want to ensure this federal agency takes more decisive action when issues are reported and meets its responsibility of making sure products are safe for consumption,” Guthrie said in a news release.”
#californiacannabis – “Department of Cannabis Control (DCC). The budget provides DCC with $201.6 million, primarily from the Cannabis Control Fund, which is supported largely by licensing fees. This is a net decrease of $92.1 million (31 percent) from the revised 2021-22 level. This decrease is primarily due to the expiration of one-time General Fund support provided in 2021-22 related to assisting individuals in participating in the cannabis market. This decrease is partially offset by various augmentations, including the following:
$20.5 million one time from the General Fund in 2022-23 for the Cannabis Local Jurisdiction Retail Access Grant Program to provide funding to cities and counties that do not currently have a local cannabis retailer licensing program, in order to aid them in developing such programs.
$13.6 million one time from the Cannabis Tax Fund in 2022-23 for an IT assessment of a unified cannabis licensing system, consumer awareness campaign, and data collection and sharing efforts.”
#californiacannabis – “Senate Bill 1186, alongside other technical fixes to the Medicinal and Adult-Use Cannabis Regulation and Safety Act, creates the Medicinal Cannabis Patients’ Right of Access Act (“Act”). Its main function is that, as of January 1, 2024, no local jurisdiction can
adopt or enforce any regulation that prohibits the retail sale by delivery within the local jurisdiction of medicinal cannabis to medicinal cannabis patients or their primary caregivers, or that otherwise has the effect of prohibiting the retail sale by delivery within the local jurisdiction of medicinal cannabis to medicinal cannabis patients or their primary caregivers by licensed medicinal cannabis businesses in a timely and readily accessible manner, and in types and quantities that are sufficient to meet demand from medicinal cannabis patients within the local jurisdiction…..
The Act also intelligently prohibits local government’s use of de facto bans on medical cannabis delivery via severe restrictions on:
The number of medicinal cannabis businesses authorized to deliver medicinal cannabis in the local jurisdiction.
The operating hours of medicinal cannabis businesses.
The number or frequency of sales by delivery of medicinal cannabis.
The types or quantities of medicinal cannabis authorized to be sold by delivery.
The establishment of physical premises from which retail sale by delivery of medicinal cannabis within the jurisdiction is conducted by a licensed non-storefront retailer (except that this prohibition doesn’t require the establishment of additional physical premises in a local jurisdiction that allowed medicinal cannabis retail as of January 1, 2022, and in which at least one physical premises engaged in the retail sale of medicinal cannabis, whether storefront or delivery, is already established).”